Molecular Early Detection for Pancreatic Cancer in High-Risk Individuals: Are We Sure Yet?
In the United States, ductal adenocarcinoma of the pancreas (PDAC) is the tenth most common incident cancer and the third most common cause of cancer deaths.1 Although most cases are sporadic, those carrying neoplastic cysts, familial predisposition, or PDAC-associated pathogenic germline variants have the highest incidence and are now included in surveillance guidelines.2 Observational studies have demonstrated improved surgical candidacy and apparent survival for high-risk individuals enrolled in surveillance programs, even after adjusting for potential lead-time effects from an earlier diagnosis.
